SPOTLIGHT: Election 2008: What does it mean for drugmakers?

The winner of the 2008 election will be faced with making key decisions on a number of issues important to drug developers. Questions as to whether there will be more federal funding for stem cell research, a faster path for biogenerics, or a change to the structure of the nation's healthcare system will have to be addressed by the next president, and how they tackle those issues will have serious repercussions for the industry. Here's a look at the four front-runners' stance on several topics vital to the biotech and pharmaceutical industries. Report